 |
PDBsum entry 2n8f
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
| |
|
DOI no:
|
Proc Natl Acad Sci U S A
114:3750-3755
(2017)
|
|
PubMed id:
|
|
|
|
|
| |
|
Potent neuroprotection after stroke afforded by a double-knot spider-venom peptide that inhibits acid-sensing ion channel 1a.
|
|
I.R.Chassagnon,
C.A.McCarthy,
Y.K.Chin,
S.S.Pineda,
A.Keramidas,
M.Mobli,
V.Pham,
T.M.De Silva,
J.W.Lynch,
R.E.Widdop,
L.D.Rash,
G.F.King.
|
|
|
|
| |
ABSTRACT
|
|
|
| |
|
Stroke is the second-leading cause of death worldwide, yet there are no drugs
available to protect the brain from stroke-induced neuronal injury. Acid-sensing
ion channel 1a (ASIC1a) is the primary acid sensor in mammalian brain and a key
mediator of acidosis-induced neuronal damage following cerebral ischemia.
Genetic ablation and selective pharmacologic inhibition of ASIC1a reduces
neuronal death following ischemic stroke in rodents. Here, we demonstrate that
Hi1a, a disulfide-rich spider venom peptide, is highly neuroprotective in a
focal model of ischemic stroke. Nuclear magnetic resonance structural studies
reveal that Hi1a comprises two homologous inhibitor cystine knot domains
separated by a short, structurally well-defined linker. In contrast with known
ASIC1a inhibitors, Hi1a incompletely inhibits ASIC1a activation in a
pH-independent and slowly reversible manner. Whole-cell, macropatch, and
single-channel electrophysiological recordings indicate that Hi1a binds to and
stabilizes the closed state of the channel, thereby impeding the transition into
a conducting state. Intracerebroventricular administration to rats of a single
small dose of Hi1a (2 ng/kg) up to 8 h after stroke induction by occlusion of
the middle cerebral artery markedly reduced infarct size, and this correlated
with improved neurological and motor function, as well as with preservation of
neuronal architecture. Thus, Hi1a is a powerful pharmacological tool for probing
the role of ASIC1a in acid-mediated neuronal injury and various neurological
disorders, and a promising lead for the development of therapeutics to protect
the brain from ischemic injury.
|
|
|
|
|
|
|
 |
 |
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
');
}
}
 |